









市场行情
/
股票
/
nasdaq-nsrx
/

Nasus Pharma Ltd

NSRX

7.260USD

+0.890+13.97%

收盘 12/19, 16:00（美东）报价延迟15分钟

65.77M总市值

亏损市盈率 TTM



Nasus Pharma Ltd

7.260

+0.890+13.97%

概览公司财务分析

概览

公司

财务

分析

关于 Nasus Pharma Ltd 公司

Nasus Pharma Ltd is an Israel-based pharmaceutical company. The Company conducts ins business activities as a pharmaceutical preparation and intranasal powder-based drug delivery systems manufacturer. Its microsphere technology enables rapid, non-invasive administration of medications for conditions such as anaphylaxis and opioid overdose among others. Nasus Pharma Ltd's formulations are designed for relatively fast absorption, ease of use, and effectiveness in critical situations (such as emergency use). The Company's products predominantly aim to improve access to life-saving treatments by allowing easy administration by caregivers or non-professionals, as well as medical doctors and emergency nurses.

Nasus Pharma Ltd简介



公司代码NSRX

公司名称Nasus Pharma Ltd

上市日期Aug 13, 2025

CEOTeleman (Dan)

员工数量- -

证券类型Ordinary Share

年结日Aug 13

公司地址Yigal Alon 65

城市TEL AVIV-YAFO

上市交易所NASDAQ OMX – NASDAQ Basic Amex

国家Israel

邮编- -

电话97237326616

网址https://www.nasuspharma.com

公司代码NSRX

上市日期Aug 13, 2025

CEOTeleman (Dan)

Nasus Pharma Ltd公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Udi Gilboa

Co-Founder, Executive Chairman of the Board of Director

1.90M

+3.00%

Dr. Dalia Megiddo

Co-Founder, Director, Chief Development Officer and Chief Medical Officer

1.89M

+2.32%

Mr. David Silberman, CPA

Independent Director Nominee

Mr. Oren Elmaliach

Director of Finance

Dr. Tair Lapidot, Ph.D.

Vice President of Research and Development and Clinical Development

Galia Temtsin Kryaz

Director of CMC and Product Development

Mr. Ronnie Hershman

Independent Director

Isaac Israel

Independent Director Nominee

Dr. Sharon Shacham, Ph.D.

Independent Director Nominee

Mr. Dan Teleman

Chief Executive Officer

名称

名称/职务

职务

持股

持股变动

Mr. Udi Gilboa

Co-Founder, Executive Chairman of the Board of Director

1.90M

+3.00%

Dr. Dalia Megiddo

Co-Founder, Director, Chief Development Officer and Chief Medical Officer

1.89M

+2.32%

Mr. David Silberman, CPA

Independent Director Nominee

Mr. Oren Elmaliach

Director of Finance

Dr. Tair Lapidot, Ph.D.

Vice President of Research and Development and Clinical Development

Galia Temtsin Kryaz

Director of CMC and Product Development

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月17日周一

持股股东

股东类型

持股股东

占比

Gilboa (Udi)

21.09%

Megiddo (Dalia)

20.96%

Hershman Holdings L.L.C.

9.89%

Capital Point Ltd

6.38%

Phoenix Solutions Ltd

4.76%

其他

36.92%

持股股东

占比

Gilboa (Udi)

21.09%

Megiddo (Dalia)

20.96%

Hershman Holdings L.L.C.

9.89%

Capital Point Ltd

6.38%

Phoenix Solutions Ltd

4.76%

其他

36.92%

股东类型

持股股东

占比

Individual Investor

43.95%

Corporation

21.03%

Investment Advisor

0.04%

其他

34.98%

机构持股



更新时间: 9月12日周五

报告期

机构数

持股数

持股占比

持股变动

2025Q3

5.35M

59.33%

+5.35M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Gilboa (Udi)

1.85M

20.48%

+1.85M

Aug 12, 2025

Megiddo (Dalia)

1.85M

20.48%

+1.85M

Aug 12, 2025

Hershman Holdings L.L.C.

477.01K

5.29%

+477.01K

Aug 12, 2025

Capital Point Ltd

575.13K

6.38%

+575.13K

Aug 14, 2025

Phoenix Solutions Ltd

429.31K

4.76%

+429.31K

Aug 12, 2025

Krayz (Galia Temtsin)

171.72K

1.91%

+171.72K

Aug 12, 2025

Lapidot (Tair Ph.D.)

10.00

+10.00

Aug 12, 2025

持股ETF



机构名称

占比

暂无数据

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Nasus Pharma Ltd的前五大股东是谁？



Nasus Pharma Ltd 的前五大股东如下：
Gilboa (Udi)持有股份：1.85M，占总股份比例：20.48%。
Megiddo (Dalia)持有股份：1.85M，占总股份比例：20.48%。
Hershman Holdings L.L.C.持有股份：477.01K，占总股份比例：5.29%。
Capital Point Ltd持有股份：575.13K，占总股份比例：6.38%。
Phoenix Solutions Ltd持有股份：429.31K，占总股份比例：4.76%。